The French Competition Authority fines a pharmaceutical company for having implemented a strategy of denigrating the generic versions of its branded drug (Sanofi-Aventis)

France: The Autorité de la Concurrence fines Sanofi-Aventis € 40 600 000 for denigrating Generic Versions of branded Drug Plavix* On 14 May 2013, following a complaint from the generics manufacturer Teva Santé, the Autorité de la concurrence (the Autorité) imposed a fine of € 40 600 000 on Sanofi-Aventis for having implemented a strategy of denigrating the generic versions of its branded drug, Plavix, vis-à-vis pharmacists and doctors, with the goal of limiting their entry on the market and favoring Sanofi-Aventis’ Plavix as well as its own generic version Clopidogrel Winthrop. It found that Sanofi–Aventis had abused its dominant position, thereby infringing Article 102 TFEU as well as the corresponding French provision. A prior decision was handed down by the Autorité in 2010, dismissing

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Competition Network Brief, The French Competition Authority fines a pharmaceutical company for having implemented a strategy of denigrating the generic versions of its branded drug (Sanofi-Aventis), 14 May 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 53327

Visites 202

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues